United States · Platforms & data · Morningstar

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

Published by Morningstar · United States 10 h ago

Supports serial testing in the surveillance setting for patients with early-stage HCC Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

MarketBeat

It’s finally Election Day — and prediction markets may show ‘too much confidence in a good night for Democrats’

Investing.com

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

Share

Also worth reading

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

It’s finally Election Day — and prediction markets may show ‘too much confidence in a good night for Democrats’

Treasury yields edge up as Election Day meets JOLTS, refunding